Dr. Yaroslau Compta discusses how the view of co-pathologies has changed the view of many disorders, including tauopathies. He dives into the current state of clinical trials for PSP and what those results may mean for the future of biomarkers.
Read MoreRehabilitation for movement disorders, like PD, has become increasingly prevalent for patient care. Prof. Alice Nieuwboer discusses how technology has shaped the field, how neurologists can support patient exercise, and what future updates she looks forward to.
Read MoreThere have been nearly 30 years of disease modifying trials for PD, but little success. Prof. Tanya Simuni breaks down clinical trial design for a heterogenous disease like PD and discusses the future goals and importance of a biological definition.
Read MoreDue to genetic advancements, the pediatric movement disorder field is ever growing. Dr. Shekeeb Mohammad breaks down the current landscape of the field and how adult neurologists can advance their learning.
Read MoreThe field of genetics often moves quickly, making it a challenge to stay informed. Dr. Gerard Saranza breaks down the current landscape, new discoveries and technologies, and what changes we can expect in the upcoming years.
Read MoreDr. Victor Fung reflects on his term as MDS President and his appreciation for the accomplishments that were achieved. He further discusses his future hopes and goals of the Society and the #mdscongress.
Read More
La Dra. Isabel Enríquez, en conjunto con el Dr. DavidJosé Heredia, ambos oncólogos médicos mexicanos, comparten su análisis de losestudios más relevantes presentados durante el tercer día del Congreso Anual dela Sociedad Europea de Oncología Médica 2025, celebrado en Berlín, con base enla información disponible al momento de esta grabación. Los trabajos comentados son: Cáncer de…
Read More
En esta cápsula de ESMO 2025 EXPRESS, el Dr. Juan Manuel O’Connor, oncólogo médico, jefe de la sección de Tumores Gastrointestinales del Instituto Alexander Fleming en Buenos Aires, Argentina nos comenta brevemente sobre los avances más relevantes sobre tumores gastrointestinales. El experto comenta lo siguiente: Ya se presentaron los datos del estudio MATTERHORN con resultados…
Read More
En esta cápsula de ESMO 2025 EXPRESS, el Dr. Gonzalo Giornelli, oncólogo clínico y jefe del Departamento de Gineco-Oncología del Instituto Alexander Fleming en Buenos Aires, Argentina, nos comenta brevemente los avances más relevantes en tumores ginecológicos presentados durante el congreso ESMO 2025. El gran protagonista de este ESMO fue, sin duda, el cáncer de…
Read More
En esta cápsula de ESMO 2025 EXPRESS, el Dr. Luis Corrales, oncólogo médico adscrito al Centro de Investigación y Manejodel Cáncer en San José, Costa Rica, nos habló sobre los principales avances presentados en oncología torácica. El experto comenta lo siguiente: Durante el Congreso Anual de la Sociedad Europea de Oncología Médica 2025,…
Read More